HIV-1 Drug Resistance in Subjects with Advanced HIV-1 Infection in Whom Antiretroviral Combination Therapy Is Failing: A Substudy of AIDS Clinical Trials Group Protocol 388

• Published in: Clinical infectious diseases Vol. 39; no. 4; pp. 552 - 558
• Main Authors: Demeter, Lisa M., Ribaudo, Heather J., Erice, Alejo, Eshleman, Susan H., Hammer, Scott M., Hellmann, Nicholas S., Fischl, Margaret A.
• Format: Journal Article
• Language: English
• Published: United States The University of Chicago Press 15.08.2004; University of Chicago Press
• Subjects: Acquired Immunodeficiency Syndrome - drug therapy; Adult; AIDS; Antiretroviral Therapy, Highly Active - methods; Antiretrovirals; Antivirals; Clinical trials; Drug resistance; Drug Resistance, Viral - physiology; Female; Genetic mutation; Genotype; HIV 1; HIV Infections - drug therapy; HIV Infections - metabolism; HIV Reverse Transcriptase - blood; HIV Reverse Transcriptase - genetics; HIV-1 - drug effects; HIV-1 - enzymology; HIV-1 - genetics; HIV-1 - physiology; HIV/AIDS; Human immunodeficiency virus 1; Humans; Indinavir - administration & dosage; Indinavir - metabolism; Lamivudine - administration & dosage; Lamivudine - metabolism; Male; Memory interference; Nelfinavir - administration & dosage; Nelfinavir - metabolism; Phenotype; Stavudine - administration & dosage; Stavudine - metabolism; Treatment Failure; Virology; Viruses; Zidovudine - administration & dosage; Zidovudine - metabolism
• ISSN: 1058-4838; 1537-6591
• DOI: 10.1086/422518

We evaluated phenotypic and genotypic markers of drug resistance in human immunodeficiency virus type 1 (HIV-1) at the time of virologic failure (VF) in subjects in the AIDS Clinical Trials Group Protocol 388 (ACTG 388) who received lamivudine-zidovudine (or lamivudine-stavudine) and either indinavir, efavirenz-indinavir, or nelfinavir-indinavir. At VF, phenotypically susceptible HIV-1 was found in 55% of subjects in the nelfinavir-indinavir arm, compared with 22% in the indinavir arm (P = .006). Phenotypic resistance to lamivudine was less common in the efavirenz-indinavir arm (33% of subjects; P = .002) and the nelfinavir-indinavir arm (43%; P = .003), compared with the indinavir arm (78%). Isolated phenotypic resistance to efavirenz at VF occurred in HIV-1 recovered from 33% of subjects in the efavirenz-indinavir arm; 24% of the subjects had HIV-1 with both efavirenz and lamivudine resistance. Results of genotypic tests were similar. The lower frequency of resistance in the nelfinavir-indinavir arm likely reflects decreased drug exposure that is due to intolerance, which is consistent with the lower potency and tolerability of this combination in ACTG 388. The lower frequency of lamivudine resistance in the efavirenz-indinavir arm is consistent with reports in other studies of potent regimens. Thus, although dual resistance to efavirenz and lamivudine occurred at VF in the efavirenz-indinavir arm, this risk was relatively low when evaluated in the context of the potency and tolerability of this regimen.